Monopar Therapeutics (NASDAQ:MNPR) Trading 6.3% Higher – Here’s Why

Monopar Therapeutics Inc. (NASDAQ:MNPR) shares traded up 6.3% during trading on Friday . The stock traded as high as $84.63 and last traded at $84.5050. 21,755 shares were traded during trading, a decline of 64% from the average session volume of 60,100 shares. The stock had previously closed at $79.47.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on MNPR shares. Barclays set a $125.00 target price on Monopar Therapeutics and gave the stock an “overweight” rating in a report on Monday, October 13th. Lake Street Capital assumed coverage on shares of Monopar Therapeutics in a research note on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price target on the stock. BTIG Research boosted their price objective on shares of Monopar Therapeutics from $87.00 to $104.00 and gave the company a “buy” rating in a research report on Thursday, September 25th. Piper Sandler set a $95.00 price target on shares of Monopar Therapeutics and gave the company an “overweight” rating in a research note on Thursday, September 25th. Finally, Leerink Partners initiated coverage on shares of Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $106.20.

Monopar Therapeutics Stock Performance

The firm has a fifty day moving average price of $85.23 and a 200 day moving average price of $55.68. The stock has a market cap of $548.74 million, a PE ratio of -24.03 and a beta of 1.46.

Monopar Therapeutics (NASDAQ:MNPR) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.46) by ($0.02). On average, equities research analysts forecast that Monopar Therapeutics Inc. will post -1.65 earnings per share for the current year.

Insider Buying and Selling

In other Monopar Therapeutics news, major shareholder Tactic Pharma Llc sold 550,229 shares of Monopar Therapeutics stock in a transaction that occurred on Wednesday, September 24th. The shares were sold at an average price of $63.61, for a total transaction of $35,000,066.69. Following the completion of the sale, the insider directly owned 272,026 shares in the company, valued at approximately $17,303,573.86. The trade was a 66.92% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Insiders own 20.50% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in MNPR. Russell Investments Group Ltd. purchased a new stake in Monopar Therapeutics in the third quarter valued at $28,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Monopar Therapeutics in the 2nd quarter valued at about $34,000. AlphaQuest LLC purchased a new stake in shares of Monopar Therapeutics in the first quarter worth about $44,000. BNP Paribas Financial Markets grew its holdings in Monopar Therapeutics by 100.6% during the third quarter. BNP Paribas Financial Markets now owns 696 shares of the company’s stock worth $57,000 after acquiring an additional 349 shares during the period. Finally, JPMorgan Chase & Co. grew its holdings in Monopar Therapeutics by 1,821.0% during the second quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company’s stock worth $69,000 after acquiring an additional 1,821 shares during the period. 1.83% of the stock is currently owned by institutional investors and hedge funds.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.